Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US10906975B2 · kind B2 · utility
1Cited by
70References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 4, 2018 |
| Grant date | Feb 2, 2021 |
| Priority date | — |
| Expiry date | Dec 4, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.